BIOLASE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 09, 2023 at 04:53 pm EST
Share
BIOLASE, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 10.92 million compared to USD 12.01 million a year ago. Net loss was USD 4.59 million compared to USD 8.39 million a year ago. Basic loss per share from continuing operations was USD 3.89 compared to USD 110.36 a year ago. Diluted loss per share from continuing operations was USD 3.89 compared to USD 110.36 a year ago.
For the nine months, sales was USD 35.67 million compared to USD 34.41 million a year ago. Net loss was USD 15.31 million compared to USD 18.77 million a year ago. Basic loss per share from continuing operations was USD 22.28 compared to USD 287.73 a year ago. Diluted loss per share from continuing operations was USD 22.28 compared to USD 287.73 a year ago.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company's systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. The Company's all-tissue Waterlase dental laser systems consist of its flagship Waterlase iPlus, Waterlase Express, and Waterlase MDX. Its soft tissue diode laser systems consist of the Epic X, Epic Hygiene, Epic Q, and Epic 10 diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief. Epic X, and Epic 10 systems feature its 940 nanometer wavelength with patented pulse technology called ComfortPulse.
BIOLASE, INC. 
